Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 10/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 2/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.40 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.40 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.40 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.40 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.40 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23998064 | 1.00 | DGAT1 (0.47) | DGAT1SYKHCRTR1BRAFCCNA2 | |
| SCHEMBL21910309 | 1.00 | DGAT1 (0.47) | DGAT1SYKHCRTR1BRAFCCNA2 | |
| SCHEMBL16674551 | 0.88 | GSK3B (0.47) | DGAT1SYKHCRTR1BRAF | |
| SCHEMBL19019015 | 0.84 | FGFR4 (0.55) | DGAT1SYKHCRTR1CCNA2CDK2 | |
| SCHEMBL21910310 | 0.84 | FGFR4 (0.55) | DGAT1SYKHCRTR1CCNA2CDK2 | |
| SCHEMBL21910317 | 0.82 | FGFR4 (0.62) | CYP2C8FGFR1CYP2C9CYP2B6FGFR2 | |
| SCHEMBL16683516 | 0.82 | FGFR4 (0.62) | CYP2C8FGFR1CYP2C9CYP2B6FGFR2 | |
| SCHEMBL23998140 | 0.82 | FGFR4 (0.62) | CYP2C8FGFR1CYP2C9CYP2B6FGFR2 | |
| SCHEMBL24335656 | 0.81 | FGFR4 (0.63) | CYP2C8FGFR1CYP2C9CYP2B6FGFR2 | |
| SCHEMBL16674570 | 0.81 | FGFR4 (0.63) | CYP2C8FGFR1CYP2C9CYP2B6FGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10221154-B2 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION (US) | 2019-03-05 | — | — | US | disclosed |
| US-20170174652-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174652-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR4, FGFR1, FGFR2 | DGAT1 2904/4885SYK 759/4885HCRTR1 4712/4885 |
| US-10221154-B2 | Inhibitors of the fibroblast growth factor receptor | FGFR4, FGFR1, FGFR2 | DGAT1 2904/4885SYK 759/4885HCRTR1 4712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.